Information Provided By:
Fly News Breaks for February 17, 2020
Feb 17, 2020 | 12:56 EDT
UBS analyst Kevin Caliendo raised his price target for Teva to $14 from $8, while keeping a Neutral rating on the shares as he awaits clarity on litigation costs.
News For TEVA From the Last 2 Days
May 4, 2021 | 06:09 EDT
UBS analyst Kevin Caliendo downgraded Teva to Neutral from Buy with a price target of $11, down from $15. The analyst is citing the company's reduced visibility on meeting long-term targets as Q1 saw a slow performance from key products Ajovy and Austedo. Caliendo further notes the increased uncertainty around legal outcomes along with weak cash flows and declining reserves for Teva.